Introduction: The objectives of the study were to examine the opinions of urology specialists on whether there are actual differences in efficacy among α1-blockers and to identify the factors that should be considered when prescribing these medications according to age. Methods: We surveyed 50 South Korean urology specialists with over 3 years of clinical experience in secondary or tertiary hospitals in July-August 2021. The survey covered urologists' demographics, awareness of α1-blocker prescription differences, and key factors in α1-blocker selection based on LUTS severity and patient age. Results: Overall, 82% of the respondents believed that there were differences in the efficacy of α1-blockers in actual practice according to age. Over 90% of the respondents agreed on the need for head-to-head comparison studies to compare the effects of different α1-blockers. Regardless of the severity of LUTS, urologists prioritize cardiovascular side effects when prescribing α1-blockers to patients aged ≥70 years. Further, 19% of the urologists prioritized ejaculatory side effects for mild-to-moderate LUTS and 9% for severe LUTS (p < 0.001). Conclusions: This study shows that head-to-head studies comparing the efficacy of different α1-blockers are highly valuable for the real-world clinical application of α1-blockers. Notably, urologists prioritize cardiovascular and ejaculatory side effects in older and younger patients while prescribing α1-blockers, respectively.

1.
Berry
SJ
,
Coffey
DS
,
Walsh
PC
,
Ewing
LL
.
The development of human benign prostatic hyperplasia with age
.
J Urol
.
1984
;
132
(
3
):
474
9
.
2.
Welch
G
,
Weinger
K
,
Barry
MJ
.
Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study
.
Urology
.
2002
;
59
(
2
):
245
50
.
3.
McVary
KT
,
Roehrborn
CG
,
Avins
AL
,
Barry
MJ
,
Bruskewitz
RC
,
Donnell
RF
, et al
.
Update on AUA guideline on the management of benign prostatic hyperplasia
.
J Urol
.
2011
;
185
(
5
):
1793
803
.
4.
Kumar
VL
,
Dewan
S
.
Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate
.
Int Urol Nephrol
.
2000
;
32
(
1
):
67
71
.
5.
Kenny
BA
,
Miller
AM
,
Williamson
IJR
,
O’Connell
J
,
Chalmers
DH
,
Naylor
AM
.
Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies
.
Br J Pharmacol
.
1996
;
118
(
4
):
871
8
.
6.
Djavan
B
,
Chapple
C
,
Milani
S
,
Marberger
M
.
State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
.
Urology
.
2004
;
64
(
6
):
1081
8
.
7.
Djavan
B
,
Marberger
M
,
Chapple
CR
.
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
.
Eur Urol
.
1999
;
36
(
1
):
1
13
.
8.
De Mey
C
,
Michel
MC
,
McEwen
J
,
Moreland
T
.
A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
.
Eur Urol
.
1998
;
33
(
5
):
481
8
.
9.
Milani
S
,
Djavan
B
.
Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists
.
BJU Int
.
2005
;
95
(
Suppl 4
):
29
36
.
10.
Gacci
M
,
Ficarra
V
,
Sebastianelli
A
,
Corona
G
,
Serni
S
,
Shariat
SF
, et al
.
Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis
.
J Sex Med
.
2014
;
11
(
6
):
1554
66
.
11.
Rosenberg
MT
,
Staskin
DR
,
Kaplan
SA
,
MacDiarmid
SA
,
Newman
DK
,
Ohl
DA
.
A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting
.
Int J Clin Pract
.
2007
;
61
(
9
):
1535
46
.
12.
Parsons
JK
,
Mougey
J
,
Lambert
L
,
Wilt
TJ
,
Fink
HA
,
Garzotto
M
, et al
.
Lower urinary tract symptoms increase the risk of falls in older men
.
BJU Int
.
2009
;
104
(
1
):
63
8
.
13.
Ichihara
K
,
Masumori
N
,
Iwasawa
A
,
Taguchi
K
,
Yamaguchi
Y
,
Nishimura
M
, et al
.
Silodosin as second-line α-blocker monotherapy in patients with benign prostatic hyperplasia: a prospective observational study
.
Int J Urol
.
2018
;
25
(
10
):
849
54
.
14.
Masciovecchio
S
,
Di Pasquale
AB
,
Ranieri
G
,
Romano
G
,
Di Clemente
L
.
Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
.
Eur Rev Med Pharmacol Sci
.
2017
;
21
(
21
):
4941
5
.
15.
Kosugi
S
,
Ikemoto
I
,
Furuta
A
,
Shimomura
T
,
Kiyota
H
,
Suzuki
Y
, et al
.
A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder
.
Jpn J Urol
.
2007
;
98
(
5
):
691
9
.
16.
Karadağ
E
,
Öner
S
,
Budak
YU
,
Atahan
Ö
.
Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia
.
Int Urol Nephrol
.
2011
;
43
(
4
):
949
54
.
17.
Kojima
Y
,
Sasaki
S
,
Hayashi
Y
,
Tsujimoto
G
,
Kohri
K
.
Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine
.
Nat Clin Pract Urol
.
2009
;
6
(
1
):
44
53
.
18.
De Mey
C
.
Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials
.
Eur Urol
.
2000
;
38
(
Suppl 1
):
25
39
.
19.
Buzelin
JM
,
Fonteyne
E
,
Kontturi
M
,
Witjes
WPJ
,
Khan
A
.
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group
.
Br J Urol
.
1997
;
80
(
4
):
597
605
.
20.
Novara
G
,
Tubaro
A
,
Sanseverino
R
,
Spatafora
S
,
Artibani
W
,
Zattoni
F
, et al
.
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement
.
World J Urol
.
2013
;
31
(
4
):
997
1008
.
21.
Novara
G
,
Chapple
CR
,
Montorsi
F
.
Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH): subgroup analyses of efficacy and safety data
.
BJU Int
.
2015
;
115
(
5
):
802
14
.
22.
Lukacs
B
,
Grange
JC
,
Comet
D
.
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice
.
Urology
.
2000
;
55
(
4
):
540
6
.
23.
Andersson
KE
,
Gratzke
C
.
Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system
.
Nat Clin Pract Urol
.
2007
;
4
(
7
):
368
78
.
24.
Brawer
MK
,
Adams
G
,
Epstein
H
.
Terazosin in the treatment of benign prostatic hyperplasia. Terazosin benign prostatic hyperplasia study group
.
Arch Fam Med
.
1993
;
2
(
9
):
929
35
.
25.
Gillenwater
JY
,
Conn
RL
,
Chrysant
SG
,
Roy
J
,
Gaffney
M
,
Ice
K
, et al
.
Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study
.
J Urol
.
1995
;
154
(
1
):
110
15
.
26.
Capogrosso
P
,
Serino
A
,
Ventimiglia
E
,
Boeri
L
,
Dehò
F
,
Damiano
R
, et al
.
Effects of silodosin on sexual function - realistic picture from the everyday clinical practice
.
Andrology
.
2015
;
3
(
6
):
1076
81
.
27.
Freak-Poli
R
,
Kirkman
M
,
De Castro Lima
G
,
Direk
N
,
Franco
OH
,
Tiemeier
H
.
Sexual activity and physical tenderness in older adults: cross-sectional prevalence and associated characteristics
.
J Sex Med
.
2017
;
14
(
7
):
918
27
.
You do not currently have access to this content.